ARTH Formula
ARTH Formula, licence 80049654: active licence in Health Canada data. The French and European references below do not constitute authorisation for sale in France or an assessment of safety or efficacy.
Licensed Natural Health Products Database (LNHPD), Health Canada: licensed products, ingredients, doses, uses and risks, retrieved 27 October 2026.
Contains information licensed under the Open Government Licence – Canada (Health Canada, LNHPD)
Licence du gouvernement ouvert – Canada 2.0 (OGL-Canada 2.0)
Natural health product licensed in Canada
- Licence holder
- 1123573 BC Ltd.
- NPN or DIN-HM
- 80049654
- Status
- Active licence
- Licence date
- 25 March 2014
- Revision date
- Not provided
- Form
- Capsule
- Route of administration
- Orale
- Application type
- Non traditionnelle
If this product were sold in France
- Conditions légales
Valeriana officinalis L.: L'absence de valépotriates doit être prouvée par des rapports d'analyse. L'étiquetage doit comporter un avertissement déconseillant l'emploi aux enfants de moins de 12 ans.
arrêté du 24 juin 2014, annexe I. French orders of 9 May 2006 (nutrients), 24 June 2014 (plants) and 26 September 2016 (other substances), consolidated LEGI collection, retrieved 23 October 2026.
A daily quantity is calculated only for an explicit adult oral dosage, stated per day and in a solid unit matching the product form. Ambiguous units, liquids, powders and paediatric doses are not extrapolated. A quantity not calculated is not compared with dose limits. This analysis does not constitute authorisation for sale in France or an assessment of safety or efficacy.
Composition
| Medicinal ingredient and source | Per dosage unit, according to the source | Maximum per day, adult |
|---|---|---|
| Yucca filamentosa Source : Racine | 100.0 mg | Not calculated |
| Capsicum annuum Source : Fruit | 2.5 mg | Not calculated |
| Valeriana officinalis Source : Racine | 20.0 mg | Not calculated |
Non-medicinal ingredients
Hypromellose, Stéarate de magnésium, Cellulose microcristalline, Maltodextrine
Recommended doses in Canada
| Population | Age | Quantity per serving | Frequency |
|---|---|---|---|
| Adultes | minimum: 19.0 Année(s) | 2.0 Capsule | 3.0 Jour(s) |
Uses authorised in Canada
Helps to relieve muscle and joint pain associated with osteoarthritis. Aids in protecting against the deterioration of cartilage. A factor in maintaining good joint health. Used in herbal medicine to help relieve muscle and joint pain associated with rheumatic conditions (such as rheumatoid arthritis, osteoarthritis and/or fibrositis), and of pain associated with neuralgia (such as sciatica).
A use authorised in Canada is not an authorised health claim in the European Union. See the health claims register.
Warnings in Canada
- Contre-indications
Do not use if you are pregnant or breastfeeding. Use cautiously in patients with bleeding disorders or in those taking anticoagulants. Use cautiously in patients with or at risk for hormone sensitive cancers or conditions. Avoid in patients with known allergy to any of the ingredients. Use cautiously in patients with hypotension or in those taking antihypertensive agents. Use cautiously in patients taking hormone replacement therapy (HRT) or oral contraceptives.
- Précautions et mises en garde
Consult a health care practitioner if symptoms persist or worsen. Consult a health care practitioner prior to use if you are taking any prescription medications. Consult a health care practitioner prior to use if you have diabetes. If you have stomach ulcers or inflammation, consult a health care practitioner prior to use. Consult a health care practitioner prior to use if you have a kidney, liver or gallbladder condition. Consumption with alcohol, other medications or natural health products with sedative properties is not recommended. Some people may experience drowsiness. Exercise caution if operation heavy machinery, driving a motor vehicle or involved in activities requiring mental alertness within 2 hours of consumption. If you have intestinal obstruction, consult a health care practitioner prior to use. Consult a health care practitioner if you develop symptoms of liver trouble.
Source
Official Health Canada record, licence 80049654
The formula sold in Europe under the same name may differ. This information does not replace advice from a doctor or pharmacist.
The evidence date of this ingredient list is unknown.
Has the product changed? Photograph the packaging.